Cellectar Biosciences CLRB 深 沪
等待开盘 04-03 09:30:00 美东时间
2.55
+0.050
+2.00%
华盛通- 最 高2.625
- 今 开2.45
- 成交量 3.07万股
- 最 低 2.45
- 昨 收 2.50
- 总市值 1081.23万
- 52周最高 20.595
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 2.43
- 委 比 -39.24%
- 总股本 424.01万
- 历史最高 276000.00
- 量 比 0.56
- 振 幅 7.00%
- 历史最低 2.43
- 每 手 1
- 风险率 2.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Cellectar Biosciences Q4 EPS $(0.53) Beats $(2.29) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(2.29) by 76.89 percent. This is a 76.67 percent decrease over losses of $(0.30) per share
03-04 20:18
Cellectar BioSciences FY 2025 net loss USD 21.8 million
Cellectar BioSciences FY 2025 net loss USD 21.8 million Cellectar BioSciences reported a FY 2025 net loss of USD 21.8 million, or USD 8.35 per basic and diluted share. R&D expenses were USD 11.5 million and G&A expenses were USD 11.5 million for FY 2025, with total operating expenses of USD 23.0 mil
03-04 20:15
Earnings Scheduled For March 4, 2026
Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...
03-04 19:11
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Cellectar Biosciences plans to submit the Conditional Marketing Authorization for iopofosine I-131 to the European Medicines Agency in Q3 2026, targeting 2027 EU commercialization for Waldenström Macroglobulinemia. The company also initiated a Phase 1b study for CLR 125 in Triple Negative Breast Cancer, with early data expected mid-2026. Cellectar reported cash of $13.2 million as of Q4 2025, down from $23.3 million in 2024, and a net loss of $21...
03-04 12:15
Insights into Cellectar Biosciences's Upcoming Earnings
Cellectar Biosciences (NASDAQ:CLRB) is preparing to release its quarterly earni...
03-04 04:01
Cellectar Biosciences Announces Broad Expansion Of Its Global IP Estate, Including Newly Issued Patents Across Europe, Asia-Pacific, The Middle East, And The Americas
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling TechnologiesProvides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the
02-17 21:12
Cellectar Biosciences Secures New Patents to Strengthen Global Cancer Drug Portfolio
Cellectar Biosciences Secures New Patents to Strengthen Global Cancer Drug Portfolio Cellectar BioSciences Inc. has announced the expansion of its global intellectual property estate, with newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas. The patents cover the comp
02-17 21:05
Cellectar Biosciences Expands Global Intellectual Property Estate
Cellectar Biosciences expanded its global intellectual property portfolio with new patents across Europe, Asia-Pacific, the Middle East, and the Americas. These additions strengthen protection for its radiotherapeutic iopofosine I 131 and other programs like CLR 125, targeting triple-negative breast cancer. The company plans to file for conditional marketing approval with the EMA for iopofosine I 131 in the 3Q26 for Waldenström macroglobulinemia....
02-17 13:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
